Adeona's reaZin study meets primary outcomes
Adeona Pharmaceuticals, a developer of medicines for CNS diseases, has results from its clinical study evaluating reaZin for the dietary management of Alzheimer's disease (AD) and mild cognitive impairment (MCI). The clinical study met the primary outcome of increasing serum zinc and decreasing serum free copper. In addition, secondary outcomes of mental status as measured by three standardized cognitive tests all favored the treatment group versus the placebo group.
The treatment group showed significant reductions in serum free copper levels and elevations in serum zinc levels over the placebo group, resulting in a highly statistically significant change in the free copper to zinc ratio (-20.8%), the primary outcome of the clinical study(p < 0.0006). An average net decrease in serum free copper of 6.5microg/dL for the treatment group versus placebo group, an average net increase in serum zinc of 64.6 microg/dL for the treatment group versus the placebo group was evident.
The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), showed an average net improvement of 0.41 points in favor of the treatment group versus placebo (p < 0.36. Clinical Dementia Rating Scale-Sum of Boxes (CDR-SOB), showed an average net improvement of 0.38 points in favor of the treatment group versus placebo (p < 0.10). Mini Mental State Examination (MMSE), showed an average net improvement of 0.19 points in favor of the treatment group versus placebo (p